Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
Status:
COMPLETED
Trial end date:
2025-09-12
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.